Safety, Pharmacokinetics, and Bioequivalence Characterization of Two Different Strengths of Mesalazine Gastro-Resistant Tablets

<b>Background/Objectives</b>: Ulcerative colitis (UC), a chronic inflammatory bowel disease, affects approximately 5 million individuals worldwide, exerting a considerable influence on global health and economic systems. Among the challenges in UC management, treatment non-adherence stands out as a...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Dolores Ochoa Mazarro, Manuel Román Martínez, Samuel Martín Vílchez, Sergio Luquero-Bueno, Paola Camargo-Mamani, Mariana Frau Usoz, Cristina Martínez Ostalé, Paula Arranz, Inmaculada Gilaberte
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2025-12-01
Schriftenreihe:	Pharmaceuticals
Schlagworte:	mesalazine phase I bioequivalence healthy participants ulcerative colitis
Online-Zugang:	https://www.mdpi.com/1424-8247/18/12/1876
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!